MAIA Biotechnology, Inc.

For the period ended Dec 31, 2025. Filed Mar 23, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 23, 2026

MAIA$1.09+2.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Changes in Stockholders’ Equity

MAIA Biotechnology, Inc.

Consolidated Statements of Changes in Stockholders’ Equity

for the Year ended December 31, 2025

Preferred Stock · Common Stock · Additional Paid-In · Accumulated · Accumulated Other Comprehensive · Total Stockholders’
	Shares	Amount	Shares	Amount	Capital	Deficit	Income (Loss)	Equity
Balance at December 31, 2024	—	$—	26,157,788	$2,616	$90,897,468	$(87,234,833)	$(30,615)	$3,634,636
Issuance of restricted stock	—	—	506,823	50	618,763	—	—	618,813
Exercise of stock options	—	—	570	—	844	—	—	844
Stock-based compensation expense	—	—	—	—	2,631,652	—	—	2,631,652
Issuance of common shares in connection with At-The-Market financing, net of $327,615 of issuance costs	—	—	3,782,335	379	6,874,022	—	—	6,874,401
Issuance of common shares in connection with the Private Placement Offerings, net of $289,518 of issuance costs	—	—	7,516,987	752	6,023,757	—	—	6,024,509
Issuance of warrants in connection with the Private Placement Offerings	—	—	—	—	4,105,215	—	—	4,105,215
Exercise of warrants	—	—	659,786	66	901,512	—	—	901,578
Foreign currency translation adjustment	—	—	—	—	—	—	(19,613)	(19,613)
Net loss	—	—	—	—	—	(22,396,172)	—	(22,396,172)
Balance at December 31, 2025	—	$—	38,624,289	$3,863	$112,053,233	$(109,631,005)	$(50,228)	$2,375,863

MAIA Biotechnology, Inc.

Consolidated Statements of Changes in Stockholders’ Equity

for the Year ended December 31, 2024

Preferred Stock · Common Stock · Additional Paid-In · Accumulated · Accumulated Other Comprehensive · Total Stockholders’
	Shares	Amount	Shares	Amount	Capital	Deficit	Income (Loss)	Equity
Balance at December 31, 2023	—	$—	16,986,254	$1,699	$64,472,249	$(63,980,177)	$(16,260)	$477,511
Issuance of restricted stock	—	—	75,550	7	179,483	—	—	179,490
Exercise of stock options	—	—	120,110	12	217,146	—	—	217,158
Stock-based compensation expense	—	—	—	—	1,912,744	—	—	1,912,744
Issuance of common shares in connection with At-The-Market financing, net of $658,801 of issuance costs	—	—	3,274,360	328	9,452,867	—	—	9,453,195
Issuance of common shares in connection with the Private Placement Offerings, net of $136,456 of issuance costs	—	—	5,156,205	516	2,683,987	—	—	2,684,503
Issuance of warrants in connection with the Private Placement Offerings	—	—	—	—	1,917,075	—	—	1,917,075
Exercise of warrants	—	—	545,309	54	3,191,621	—	—	3,191,675
Reclassification of liability classified warrants to equity	—	—	—	—	6,870,296	—	—	6,870,296
Foreign currency translation adjustment	—	—	—	—	—	—	(14,355)	(14,355)
Net loss	—	—	—	—	—	(23,254,656)	—	(23,254,656)
Balance at December 31, 2024	—	$—	26,157,788	$2,616	$90,897,468	$(87,234,833)	$(30,615)	$3,634,636

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.